This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Risankizumab is a humanised IgG1 monoclonal antibody that specifically inhibits interleukin 23 (IL-23) by binding to its p19 subunit.

NICE state (1):

Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis (PsA) in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:

  • peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
  • moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
  • had 2 conventional DMARDs and at least 1 biological DMARD

Risankizumab is recommended only if the company provides it according to the commercial arrangement.

Results from the 24-week double-blind portion of the KEEPsAKE 1 trial demonstrate that risankizumab is well tolerated and effective for treating diverse clinical manifestations of PsA in patients who have had an inadequate response or intolerance to DMARD therapy (2)

Results from the 24-week, double-blind portion of this phase 3 clinical trial in patients with active PsA reveal that risankizumab was well tolerated and effective in treating patients who have experienced previous intolerance and/or inadequate response to csDMARDs or prior biological therapies (3)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.